By. Mohamed H. Derbala, MD
Date. October 31, 2023
Mohamed H. Derbala, MD, an immuno-oncology expert and a Research Scientist at MD Anderson Cancer Center, is slated to share his expertise during an exclusive interview. The discussion will revolve around pivotal inquiries concerning TIGIT and its implications in immunotherapy.
The interview will provide a comprehensive exploration of various critical facets related to TIGIT. Dr. Derbala will delve into the intricate role that TIGIT plays in immune suppression, shedding light on its function as an inhibitory receptor impacting immune cells such as T cells and natural killer (NK) cells. His extensive research and findings have significantly contributed to understanding how TIGIT regulates immune responses by dampening T cell activation and fostering immune tolerance.
During the interview, Dr. Derbala will elaborate on TIGIT’s evaluation as a potential therapeutic target. He will discuss the progress made in clinical assessments, highlighting the effectiveness observed in preclinical and early clinical trials. These evaluations demonstrate promising prospects for leveraging TIGIT as a target for immunotherapy, potentially ameliorating immune suppression in various diseases.
Another crucial topic of discussion will be the identification of biomarkers associated with anti-TIGIT treatments. Dr. Derbala’s research has been instrumental in recognizing potential biomarkers, essential for predicting and monitoring responses to TIGIT-targeted therapies. This information is invaluable for patient stratification and the development of personalized treatment approaches.
Moreover, the interview will touch upon the challenges posed by resistance to TIGIT-targeted therapies. Dr. Derbala will share insights into the diverse approaches and strategies being explored to overcome resistance. His multidisciplinary approach combines insights from immunology, molecular biology, and targeted therapies, aiming to enhance the efficacy of anti-TIGIT treatments.
Lastly, the interview will seek Dr. Derbala’s perspective on the future of anti-TIGIT therapies. His thoughts and projections will offer a glimpse into the evolving landscape of immunotherapy. His optimistic outlook is expected to highlight the potential for continued advancements and optimization of TIGIT-targeted interventions, potentially paving the way for innovative combination therapies and a more nuanced understanding of immune regulation.
Dr. Derbala’s participation in this interview is highly anticipated, given his significant contributions and pioneering work in the field of TIGIT and immunology. His insights are expected to offer valuable perspectives and a deeper understanding of TIGIT’s role in immune modulation and its potential as a target for therapeutic interventions.